LakeShore Biopharma Director Resigns

TL;DR

LakeShore Biopharma director Brenda Wu has stepped down.

AI Summary

LakeShore Biopharma Co., Ltd. announced on June 18, 2024, that Ms. Chunyuan Wu (Brenda) has resigned from its board of directors. The company, formerly known as YS Biopharma Co., Ltd. and YishengBio Co., Ltd., is headquartered in Beijing, PRC.

Why It Matters

A director's resignation can signal changes in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — This filing is a routine announcement of a director's resignation and does not contain significant financial or operational news.

Key Numbers

• 001-41598 — Commission File Number (Identifies the company's filing with the SEC)

Key Players & Entities

• LakeShore Biopharma Co., Ltd. (company) — Filer and subject of the report
• Ms. Chunyuan Wu (Brenda) (person) — Resigned director
• YS Biopharma Co., Ltd. (company) — Former company name
• YishengBio Co., Ltd (company) — Former company name
• 001-41598 (dollar_amount) — Commission file number

FAQ

Filing Documents

• ea0208032-6k_lakeshore.htm (6-K) — 12KB
• 0001213900-24-053522.txt ( ) — 13KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission file number: 001-41598 LAKESHORE BIOPHARMA CO., LTD (Exact name of registrant as specified in its charter) Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, PRC Tel: 010-89202086 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F Resignation of Ms. Chunyuan Wu (Brenda) Ms. Chunyuan Wu (Brenda) has resigned from the board of directors (the “Board”) and from her position as the chief financial officer (“CFO”) of LakeShore Biopharma Co., Ltd (the “Company”), effective on June 14, 2024. Ms. Wu has advised the Company that her resignation was due to personal reasons and not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company. Following her resignation, the Board appointed Ms. Rachel Yu, a director of the Company, as the interim CFO while the Company searches for a permanent successor as CFO. Resignation of Mr. Zengjun Xu Mr. Zengjun Xu has resigned as a director of the Company, effective on June 14, 2024. Mr. Xu has advised that his resignation was due to personal reasons and not a result of any disagreement with the Company on any matter related to the operations, policies, or practices of the Company. The Company fully appreciates Ms. Wu and Mr. Xu’s service to the Company and the Board. Following such resignation, the Board is now comprised of six members, including: (1) Mr. Dave Chenn, (2) Dr. Hui Shao (David), (3) Ms. Rachel Yu, (4) Mr. Adam Zhao, (5) Mr. Thomas Xue, and (6) Mr. Chunyang Shao. 1 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LakeShore Biopharma Co., Ltd By: /s/ Hui Shao Name: Hui Shao Title: Director and Co-Chief Executive Officer Date: June 18, 2024 2

View Full Filing

View this 6-K filing on SEC EDGAR